Structure of dossier in CTD-format

CTD Full registration dossier consists of 5 modules:

1. Module 1: ADMINISTRATIVE INFORMATION

1.1 Table of contents.

1.2. Application form.

1.3. Summary of product characteristics, labelling and instructions for medical use:

1.3.1. Summary of product characteristics.

1.3.2. Labelling.

1.3.3. Instructions for medical use.

1.3.4. Mock-ups and specimens.

1.3.5. Summary of product characteristics already approved in the manufacturer/applicant-country.

1.4. Information about the independent experts:

1.4.1. Information about the quality expert.

1.4.2. Information about the pre-clinical expert.

1.4.3. Information about clinical expert.

1.5 Specific requirements for different types of applications.

Annex to Module 1. Environmental risk assessment

MODULE 2: CTD SUMMARY

2.1. Table of contents of Modules 2 – 5.

2.2. Introduction.

2.3. Quality overall summary.

2.4. Pre-clinical overview:

2.5. Clinical overview

2.6. Pre-clinical summary

2.6.1. Pharmacology written summary.

2.6.2. Pharmacology tabulated summary.

2.6.3. Pharmacokinetics written summary.

2.6.4. Pharmacokinetics tabulated summary.

2.6.5. Toxicology written summary.

2.6.6. Toxicology tabulated summary.

2.7. Clinical summary:

2.7.1. Summary of biopharmaceutical studies and associated analytical methods.

2.7.2. Summary of clinical pharmacology studies.

2.7.3. Summary of clinical efficacy.

2.7.4. Summary of clinical safety.

2.7.5. Literature references.

2.7.6 Synopses of individual studies.

MODULE 3: QUALITY.

CHEMICAL, PHARMACEUTICAL AND BIOLOGICAL INFORMATION FOR MEDICINAL PRODUCTS CONTAINING CHEMICAL AND/OR BIOLOGICAL ACTIVE SUBSTANCES

3.1. Table of contents.

3.2. Basic data.

3.2.S. Active substance(s).

3.2.S.1. General information:

3.2.S.1.1. Nomenclature.

3.2.S.1.2. Structure.

3.2.S.1.3. General properties

3.2.S.2. Manufacture of active substance(-s):

3.2.S.2.1. Manufacturer(s).

3.2.S.2.2. Description of manufacturing process and process controls.

3.2.S.2.3. Control of materials.

3.2.S.2.4. Controls of critical steps and intermediates.

3.2.S.2.5. Process validation and/or evaluation.

3.2.S.2.6. Manufacturing process development.

3.2.S.3. Characterization of active substance(-s).

3.2.S.3.1. Elucidation of structure and other characteristics.

3.2.S.3.2. Impurities.

3.2.S.4. Control of active substance(s).

3.2.S.4.1. Specification.

3.2.S.4.2. Analytical procedures.

3.2.S.4.3. Validation of analytical procedures.

3.2.S.4.4. Batch analyses.

3.2.S.4.5. Justification of specification.

3.2.S.5. Reference standards or materials.

3.2.S.6. Container/closure system.

3.2.S.7. Stability:

3.2.S.7.1. Stability summary and conclusions.

3.2.S.7.2. Post-approval stability protocol and stability commitment.

3.2.S.7.3. Stability data.

3.2.P. Finished medicinal product:

3.2.P.1. Description and composition of the medicinal product.

3.2.P.2. Pharmaceutical development:

3.2.P.2.1. Composition of the medicinal products.

3.2.P.2.1.1. Active substance(s).

3.2.P.2.1.2. Excipients.

3.2.P.2.2. Medicinal product.

3.2.P.2.2.1. Formulation development.

3.2.P.2.2.2. Overages.

3.2.P.2.2.3. Physicochemical and biological properties.

3.2.P.2.3. Manufacturing process development.

3.2.P.2.4. Container/closure system.

3.2.P.2.5. Microbiological attributes.

3.2.P.2.6. Compatibility.

3.2.P.3. Manufacture of the medicinal product:

3.2.P.3.1. Manufacturer(s)

3.2.P.3.2. Batch formula

3.2.P.3.3. Description of manufacturing process and process controls.

3.2.P.3.4. Controls of critical steps and intermediates.

3.2.P.3.5. Process validation and/or evaluation.

3.2.P.4. Control of excipients:

3.2.P.4.1. Specifications.

3.2.P.4.2. Analytical procedures.

3.2.P.4.3. Validation of analytical procedures.

3.2.P.4.4. Justification of specifications.

3.2.P.4.5. Excipients of human or animal origin.

3.2.P.4.6. Novel excipients.

3.2.P.5. Control of medicinal product:

3.2.P.5.1. Specification(s).

3.2.P.5.2. Analytical procedures.

3.2.P.5.3. Validation of analytical procedures.

3.2.P.5.4. Batch analyses.

3.2.P.5.5. Characterization of impurities.

3.2.P.5.6. Justification of specification(s).

3.2.P.6. Reference standards and materials.

3.2.P.7.Container/closure system.

3.2.P.8. Stability:

3.2.P.8.1. Stability summary and conclusion

3.2.P.8.2. Post-approval stability protocol and stability commitment

3.2.P.8.3. Stability data

3.2.A. Appendices:

3.2.A.1. Facilities and equipment. 

3.2.A.2. Adventitious agents safety evaluation.

3.2.A.3. Novel excipients.

3.2.R. Additional information.

3.3. Literature references.

Module 4: PRE-CLINICAL STUDY REPORTS

4.1. Table of contents.

4.2. Study reports.

4.2.1. Pharmacology:

4.2.1.1. Primary pharmacodynamics.

4.2.1.2. Secondary pharmacodynamics.

4.2.1.3. Safety pharmacology.

4.2.1.4. Pharmacodynamic interactions.

4.2.2. Pharmacokinetics:

4.2.2.1. Analytical methods and validation reports.

4.2.2.2. Absorption.

4.2.2.3. Distribution.

4.2.2.4. Metabolism.

4.2.2.5. Excretion.

4.2.2.6. Pharmacokinetic interactions (pre-clinical).

4.2.2.7. Other pharmacokinetic studies.

4.2.3. Toxicology:

4.2.3.1. Single-dose toxicity.

4.2.3.2. Repeated dose toxicity.

4.2.3.3. Genotoxicity

4.2.3.4. Carcinogenicity.

4.2.3.5. Reproductive and developmental toxicity.

4.2.3.6. Local tolerance.

4.2.3.7. Other toxicity studies.

4.3. Literature references.

MODULE 5: CLINICAL STUDY REPORTS

5.1. Table of contents.

5.2. Tabular listing of all clinical studies.

5.3. Clinical study reports:

5.3.1. Reports of biopharmaceutical studies.

5.3.2. Reports of studies pertinent to pharmacokinetics using human biomaterials.

5.3.3. Reports of human pharmacokinetic studies.

5.3.4. Reports of human pharmacodynamic studies

5.3.5. Reports of efficacy and safety studies.

5.3.6. Reports of post-registration experience.

5.3.7. Samples of case reports forms and individual patient listings.

5.4. Literature references.